September 30, 2013 Guideline Summaries American College of Chest Physicians Canadian Agency for Drugs and Technologies in Health Canadian Task Force on Preventive Health Care Catalan Agency for Health Information, Assessment and Quality Centers for Disease Control and Prevention College of Family Physicians of Canada New Developer National Collaborating Centre for Mental Health National Institute for Health and Care Excellence (NICE) National Kidney Foundation U.S. Preventive Services Task Force | Announcements Annotated Bibliographies Feature NGC will be retiring the Annotated Bibliographies. This feature will no longer be available after October 9th. NGC Spotlight See the updated Mobile Device Resources page for information on the availability of full-text guidelines and/or companion documents available in downloadable versions for smart phones and hand-held devices. Revised Inclusion Criteria NGC has revised its Inclusion Criteria! Visit our updated Inclusion Criteria page to see the new criteria and send us your comments. Health Awareness Topics - October 2013 Conference News - The Guidelines International Network North America (G-I-N NA) continues to sponsor a monthly webinar series on topics of interest to the North American guideline community. Information on upcoming webinars, as well as audio files and slides from past webinars, is available on the G-I-N Web site.
U.S. Food and Drug Administration (FDA) Advisories - September 27, 2013: Tygacil (tigecycline): FDA notified health professionals and their medical care organizations of a new Boxed Warning describing an increased risk of death when intravenous Tygacil is used for FDA-approved uses as well as for non-approved uses. These changes to the Tygacil Prescribing Information are based on an additional analysis that was conducted for FDA-approved uses after FDA issuing a Drug Safety Communication about this safety concern in September 2010.
- September 25, 2013: Arzerra (ofatumumab) and Rituxan (rituximab): FDA approved changes to the prescribing information of the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab) to add new Boxed Warning information about the risk of reactivation of hepatitis B virus (HBV) infection. The revised labels also will include additional recommendations for screening, monitoring, and managing patients on these drugs to decrease this risk.
NGC's Sister Resources This email was sent to buzzhairs.health@blogger.com using GovDelivery, on behalf of: Agency for Healthcare Research and Quality (AHRQ) · 540 Gaither Road · Rockville, MD 20850 · 301-427-1364 | |
No comments:
Post a Comment